A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington's Disease.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs SBT 020 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms CHALLENGE-HD
- Sponsors Stealth BioTherapeutics
- 01 Feb 2018 Status changed from recruiting to completed.
- 07 Mar 2017 New trial record